عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

AstraZeneca and Daiichi's Breast Cancer Drug Meets Goal in Study

FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
TT
20
TT

AstraZeneca and Daiichi's Breast Cancer Drug Meets Goal in Study

FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

AstraZeneca said on Friday its experimental precision drug had slowed the progression of a common type of breast cancer in a late-stage trial, a boost for the company after its shares fell in July on results from a separate trial of the same drug for lung cancer.
The drug, datopotamab deruxtecan, which AstraZeneca is jointly developing with Japan's Daiichi Sankyo, is being closely watched by analysts and investors in part due to the promise of the class of drugs to which it belongs, known as antibody drug conjugates (ADC).
ADCs consist of tumor-seeking monoclonal antibodies that are combined with a cell-killing chemotherapy payload.
The trial data released on Friday showed the drug, abbreviated as Dato-DXd, demonstrated a statistically significant and clinically meaningful improvement in slowing the progression of a type of breast cancer in trial participants, compared to patients who received other treatments such as chemotherapy.
The trial focused on tumors that grow in response to the hormones estrogen or progesterone, which account for roughly two-thirds of breast cancer cases. The study participants' disease had spread to other parts of the body.
The British drugmaker also said that there was a "trend in improvement" in the other main goal of the study, "overall survival" of patients, but the data on that was not mature so the trial would continue as planned.
AstraZeneca shares rose 1.7% in early trading, to their highest level in more than five weeks.
AstraZeneca is simultaneously developing the drug for use in lung cancer, and while data from a separate late-stage trial released in July was positive, the market was concerned that the drug's benefits for use in lung cancer treatment might not as pronounced as hoped, leading shares to fall more than 6% on the day the data was released.
The company has not said when it will release detailed data from the lung cancer study.
Analysts see the positive results from the breast cancer trial as good for AstraZeneca, but the market is more focused on the results of a trial called MARIPOSA by Johnson & Johnson. It compares AstraZeneca’s blockbuster cancer drug Tagrisso alone with its own drug, Rybrevant, in combination with another medicine.
Those results are expected later this year.

Most Viewed

 
Varieties

Spain Says April Blackout Was Caused by Grid Failures and Poor Planning, Not a Cyberattack 

This photograph shows a general view of Barcelona at night, partially without electricity, with the Sagrada Familia seen on the right, following a massive power cut affecting the entire Iberian peninsula and the south of France, on April 28, 2025. (AFP) 
This photograph shows a general view of Barcelona at night, partially without electricity, with the Sagrada Familia seen on the right, following a massive power cut affecting the entire Iberian peninsula and the south of France, on April 28, 2025. (AFP) 
TT
20
TT

Spain Says April Blackout Was Caused by Grid Failures and Poor Planning, Not a Cyberattack 

This photograph shows a general view of Barcelona at night, partially without electricity, with the Sagrada Familia seen on the right, following a massive power cut affecting the entire Iberian peninsula and the south of France, on April 28, 2025. (AFP) 
This photograph shows a general view of Barcelona at night, partially without electricity, with the Sagrada Familia seen on the right, following a massive power cut affecting the entire Iberian peninsula and the south of France, on April 28, 2025. (AFP) 

Spain's government said Tuesday that the massive April power outage across Spain and Portugal that left tens of millions of people disconnected in seconds was caused by technical and planning errors that left the grid unable to handle a surge in voltage.

Ecological Transition Minister Sara Aagesen, who manages the nation's energy policy, told reporters that a voltage surge led to small grid failures, mainly in the south of Spain, which then cascaded to larger ones and brought the system down in the two Iberian Peninsula nations.

She ruled out that the failure was due to a cyberattack.

The outage began shortly after noon on April 28 in Spain and lasted through nightfall, disrupting businesses, transit systems, cellular networks, internet connectivity and other critical infrastructure. Spain lost 15 gigawatts of electricity, or about 60% of its supply. Portugal, whose grid is connected to Spain's, also went down. Only the countries' island territories were spared.

“All of this happened in 12 seconds, with most of the power loss happening in just five seconds,” Aagesen said.

Several technical causes contributed to the event, including “poor planning” by Spain's grid operator Red Eléctrica, which didn’t find a replacement for one power plant that was supposed to help balance power fluctuations, the minister said.

She also said that some power plants that utilities shut off preventively when the disruptions started could have stayed online to help manage the system.

Power was fully restored by the early hours of the following day.

The government's report included analysis from Spain's national security agencies, which concluded, according to the minister, there were no indications of cyber-sabotage by foreign actors.

The government had previously narrowed down the source of the outage to three power plants that tripped in southern Spain.

In the weeks following the blackout, citizens and experts were left wondering what triggered the event in a region not known for power cuts. The outage ignited a fierce debate about whether Spain's high levels of renewable power and not enough energy generated from nuclear or gas-fired power plants had something to do with the grid failing, which the government has repeatedly denied.

Spain is at the forefront of Europe's transition to renewable energy, having generated nearly 57% of its electricity in 2024 from renewable energy sources like wind, hydropower and solar. The country is also phasing out its nuclear plants.

Spanish Prime Minister Pedro Sánchez pushed back against such speculation and defended the country's rapid ramping up of renewables. He asked for patience and said that his government would not “deviate a single millimeter” from its energy transition plans, which include a goal of generating 81% of its electricity from renewable sources by 2030.